These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33892973)

  • 1. Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.
    Veeraraghavan B; Bakthavatchalam YD; Soman R; Swaminathan S; Manesh A; Nagvekar V; Nangia V
    Indian J Med Microbiol; 2021 Jul; 39(3):286-288. PubMed ID: 33892973
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 3. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
    Davido B; Fellous L; Lawrence C; Maxime V; Rottman M; Dinh A
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630191
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
    Wenzler E; Deraedt MF; Harrington AT; Danizger LH
    Diagn Microbiol Infect Dis; 2017 Aug; 88(4):352-354. PubMed ID: 28602518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
    Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
    Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment of Bacteremia Due to NDM-1-Producing
    Hobson CA; Bonacorsi S; Fahd M; Baruchel A; Cointe A; Poey N; Jacquier H; Doit C; Monjault A; Tenaillon O; Birgy A
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530600
    [No Abstract]   [Full Text] [Related]  

  • 9. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
    Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
    Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo activity of ceftazidime/avibactam and aztreonam alone or in combination against mcr-9, serine- and metallo-β-lactamases-co-producing carbapenem-resistant Enterobacter cloacae complex.
    Li W; Zhang J; Fu Y; Wang J; Liu L; Long W; Yu K; Li X; Wei C; Liang X; Wang J; Li C; Zhang X
    Eur J Clin Microbiol Infect Dis; 2024 Jul; 43(7):1309-1318. PubMed ID: 38700663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam.
    Singh R; Kim A; Tanudra MA; Harris JJ; McLaughlin RE; Patey S; O'Donnell JP; Bradford PA; Eakin AE
    J Antimicrob Chemother; 2015 Sep; 70(9):2618-26. PubMed ID: 26024868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
    Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a simple method for testing aztreonam and ceftazidime-avibactam synergy in New Delhi metallo-beta-lactamase producing Enterobacterales.
    Khan S; Das A; Vashisth D; Mishra A; Vidyarthi AJ; Gupta R; Begam NN; Kataria B; Bhatnagar S
    PLoS One; 2024; 19(5):e0303753. PubMed ID: 38758757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam.
    De la Calle C; Rodríguez O; Morata L; Marco F; Cardozo C; García-Vidal C; Río AD; Feher C; Pellicé M; Puerta-Alcalde P; Mensa J; Soriano A; Martínez JA
    Int J Antimicrob Agents; 2019 Apr; 53(4):520-524. PubMed ID: 30471403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019.
    Sader HS; Carvalhaes CG; Arends SJR; Castanheira M; Mendes RE
    J Antimicrob Chemother; 2021 Feb; 76(3):659-666. PubMed ID: 33276387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of Escherichia coli and Klebsiella pneumoniae harbouring serine- and New Delhi metallo-β-lactamases.
    Feng K; Jia N; Zhu P; Sy S; Liu Y; Dong D; Zhu S; Zhang J; Liu Y; Martins FS; Gong H; Lv Z; Yu M; Sy SKB; Zhu Y
    J Antimicrob Chemother; 2021 Oct; 76(11):2875-2883. PubMed ID: 34383928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.
    Lodise TP; Smith NM; O'Donnell N; Eakin AE; Holden PN; Boissonneault KR; Zhou J; Tao X; Bulitta JB; Fowler VG; Chambers HF; Bonomo RA; Tsuji BT
    J Antimicrob Chemother; 2020 Sep; 75(9):2622-2632. PubMed ID: 32464664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.